G. van den Brink
Leiden University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by G. van den Brink.
Journal of Crohns & Colitis | 2008
M. Duijvestein; G. van den Brink; Daan W. Hommes
Hematopoietic stem cell transplantation and mesenchymal stromal cell therapy are currently under investigation as novel therapies for inflammatory bowel diseases. Hematopoietic stem cells (HSC) are thought to repopulate the immune system and reset the immunological response to luminal antigens. Mesenchymal stromal cells (MSC) are cells that have the capacity to differentiate into wide variety of distinct cell lineages and suppress immune responses in vitro and in vivo. Recent results from animal models and early human experience in graft-versus-host disease but also Crohns Disease suggest that ex vivo expanded MSCs may have clinically useful immunomodulatory effects.
Gastroenterology & Hepatology: Open Access | 2018
Christianne J. Buskens; Saloomeh Sahami; Tjibbe J. Gardenbroek; Jp van Straalen; Mj van de Vijver; M Löwenberg; Cyriel Y. Ponsioen; G. van den Brink; Geert D’Haens; W. A. Bemelman
Until recently the appendix was mostly seen as a rudimentary part of the human intestine, but nowadays it has been demonstrated to havea distinct immunological function. Reports are emerging linking this vermiform organ to the development of ulcerative colitis (UC) and a systematic review suggests that an appendectomy could modulate the disease course.1 In addition, various animal studies have shown that the removal of the appendix prevents the development of experimental colitis, which further supports this hypothesis.2,3
Journal of Crohns & Colitis | 2014
Auke Verhaar; Radovan Dvorsky; Manon E. Wildenberg; M. Lowenberg; Maikel P. Peppelenbosch; Daan W. Hommes; G. van den Brink
P063 Identification of novel non-transcriptionally acting glucocorticoid receptor ligands that suppress T cell activation but lack adipogenic activity A. Verhaar1 *, R. Dvorsky2, M. Wildenberg3, M. Lowenberg1, M. Peppelenbosch4, D.W. Hommes5, G. van den Brink1. 1Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands, 2Max Planck Institute of Molecular Physiology, Structural Biology, Dortmund, Germany, 3Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, 4Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands, 5University of California Los Angeles, Center for Inflammatory Bowel Diseases, Los Angeles, United States
Journal of Crohns & Colitis | 2013
Tjibbe J. Gardenbroek; Christianne J. Buskens; Jp van Straalen; G. van den Brink; Geert R. D'Haens; Willem A. Bemelman
observed in the reduction for the group previously treated with biologics (p 0.24). Conclusions: The availability of controlled clinical trials has allowed investigators to count on an additional tool for the treatment of the UC. In our population we found a decrease of the disease activity measured by the Mayo score with standard doses of ADA at 12 weeks. While ADA induces a clinical remission according to the Mayo Score, no statistically significant reduction was seen for the endoscopic index in the biologics naive group, so we must consider the extension and the disease activity for this group of patients.
Journal of Crohns & Colitis | 2013
Johannan F. Brandse; Manon E. Wildenberg; J. de Bruyn; Gertjan Wolbink; M. Lowenberg; Cyriel Y. Ponsioen; G. van den Brink; Geert R. D'Haens
Journal of Crohns & Colitis | 2009
Marjolijn Duijvestein; M.H. Verwey; H.H. Fidder; G. van den Brink; Helene Roelofs; Jaap Jan Zwaginga; Willem E. Fibbe; Daan W. Hommes
Journal of Crohns & Colitis | 2014
Johannan F. Brandse; Jeroen M. Jansen; Paul A. Baars; M. Lowenberg; Cyriel Y. Ponsioen; G. van den Brink; Geert R. D'Haens
Journal of Crohns & Colitis | 2013
Manon E. Wildenberg; A. Levin; Christine Vos; Johannan F. Brandse; J. de Bruyn; Geert R. D'Haens; G. van den Brink
Journal of Crohns & Colitis | 2017
Steven Bots; Sabine Kuin; C. Ponsioen; G. van den Brink; M Löwenberg; Geert R. D'Haens
Journal of Crohns & Colitis | 2017
Liset Westera; T. van Viegen; Jenny Jeyarajah; A. Azad; Janine Bilsborough; G. van den Brink; S. Danese; G. D'Haens; Lars Eckmann; William A. Faubion; Hannelie Korf; Dermot P. McGovern; Julián Panés; Azucena Salas; William J. Sandborn; Mark S. Silverberg; Michelle I. Smith; Severine Vermeire; Stefania Vetrano; Lisa M. Shackelton; Larry Stitt; Vipul Jairath; Barrett G. Levesque; David M. Spencer; Brian G. Feagan; N. Vande Casteele